Aveta Biomics selected Natera’s Signatera ctDNA assay to measure minimal residual disease in its Phase 3 trial of APG-157, an oral immunotherapy program targeting locally advanced head and neck squamous cell carcinoma. The study will enroll up to 826 patients across resectable and unresectable cohorts and uses Signatera both to track responses and to validate earlier Phase 2 ctDNA findings in support of regulatory submissions.